Abstract
Background: Metformin use has been associated with decreased cancer risk and mortality. However, the effects of metformin on the development of colorectal adenomas, the precursors of colorectal cancers, are not defined. Aims: This study aimed to evaluate the potential effect of metformin on the incidence of colorectal adenomas in diabetic patients with previous colorectal cancer. Methods: Among 488 consecutive diabetic patients who underwent colonoscopic surveillance after curative resection of colorectal cancer between 1998 and 2008, 240 patients were enrolled in this study and were compared in two groups: 114 patients taking metformin and 126 patients not taking metformin. Patient demographics, clinical characteristics, and colorectal adenoma incidence rate were analysed. Results: After a median follow-up of 58 months, a total of 33 patients (28.9%) exhibited adenomatous colorectal polyps among the 114 patients who used metformin, compared with 58 (46.0%) patients with colorectal adenomas among the 126 patients who did not use metformin (odds ratio = 0.48, 95% confidence interval = 0.280-0.816, P= 0.008). After adjustment for clinically relevant factors, metformin use was found to be associated with a decreased incidence of colorectal adenomas (odds ratio = 0.27, 95% confidence interval = 0.100-0.758, P= 0.012) in diabetic patients with previous colorectal cancer. Metformin use in diabetic patients with previous colorectal cancer is associated with a lower risk of colorectal adenoma.
| Original language | English |
|---|---|
| Pages (from-to) | 1042-1047 |
| Number of pages | 6 |
| Journal | Digestive and Liver Disease |
| Volume | 44 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - 2012 Dec 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Hepatology
- Gastroenterology
Cite this
}
Metformin use is associated with a decreased incidence of colorectal adenomas in diabetic patients with previous colorectal cancer. / Lee, Jin Ha; Jeon, Soung Min; Hong, Sung Pil; Cheon, Jae Hee; Kim, Tae Il; Kim, Won Ho.
In: Digestive and Liver Disease, Vol. 44, No. 12, 01.12.2012, p. 1042-1047.Research output: Contribution to journal › Article
TY - JOUR
T1 - Metformin use is associated with a decreased incidence of colorectal adenomas in diabetic patients with previous colorectal cancer
AU - Lee, Jin Ha
AU - Jeon, Soung Min
AU - Hong, Sung Pil
AU - Cheon, Jae Hee
AU - Kim, Tae Il
AU - Kim, Won Ho
PY - 2012/12/1
Y1 - 2012/12/1
N2 - Background: Metformin use has been associated with decreased cancer risk and mortality. However, the effects of metformin on the development of colorectal adenomas, the precursors of colorectal cancers, are not defined. Aims: This study aimed to evaluate the potential effect of metformin on the incidence of colorectal adenomas in diabetic patients with previous colorectal cancer. Methods: Among 488 consecutive diabetic patients who underwent colonoscopic surveillance after curative resection of colorectal cancer between 1998 and 2008, 240 patients were enrolled in this study and were compared in two groups: 114 patients taking metformin and 126 patients not taking metformin. Patient demographics, clinical characteristics, and colorectal adenoma incidence rate were analysed. Results: After a median follow-up of 58 months, a total of 33 patients (28.9%) exhibited adenomatous colorectal polyps among the 114 patients who used metformin, compared with 58 (46.0%) patients with colorectal adenomas among the 126 patients who did not use metformin (odds ratio = 0.48, 95% confidence interval = 0.280-0.816, P= 0.008). After adjustment for clinically relevant factors, metformin use was found to be associated with a decreased incidence of colorectal adenomas (odds ratio = 0.27, 95% confidence interval = 0.100-0.758, P= 0.012) in diabetic patients with previous colorectal cancer. Metformin use in diabetic patients with previous colorectal cancer is associated with a lower risk of colorectal adenoma.
AB - Background: Metformin use has been associated with decreased cancer risk and mortality. However, the effects of metformin on the development of colorectal adenomas, the precursors of colorectal cancers, are not defined. Aims: This study aimed to evaluate the potential effect of metformin on the incidence of colorectal adenomas in diabetic patients with previous colorectal cancer. Methods: Among 488 consecutive diabetic patients who underwent colonoscopic surveillance after curative resection of colorectal cancer between 1998 and 2008, 240 patients were enrolled in this study and were compared in two groups: 114 patients taking metformin and 126 patients not taking metformin. Patient demographics, clinical characteristics, and colorectal adenoma incidence rate were analysed. Results: After a median follow-up of 58 months, a total of 33 patients (28.9%) exhibited adenomatous colorectal polyps among the 114 patients who used metformin, compared with 58 (46.0%) patients with colorectal adenomas among the 126 patients who did not use metformin (odds ratio = 0.48, 95% confidence interval = 0.280-0.816, P= 0.008). After adjustment for clinically relevant factors, metformin use was found to be associated with a decreased incidence of colorectal adenomas (odds ratio = 0.27, 95% confidence interval = 0.100-0.758, P= 0.012) in diabetic patients with previous colorectal cancer. Metformin use in diabetic patients with previous colorectal cancer is associated with a lower risk of colorectal adenoma.
UR - http://www.scopus.com/inward/record.url?scp=84868302293&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84868302293&partnerID=8YFLogxK
U2 - 10.1016/j.dld.2012.06.007
DO - 10.1016/j.dld.2012.06.007
M3 - Article
C2 - 22789400
AN - SCOPUS:84868302293
VL - 44
SP - 1042
EP - 1047
JO - Digestive and Liver Disease
JF - Digestive and Liver Disease
SN - 1590-8658
IS - 12
ER -